SCHEMBL25607673

SCHEMBL25607673

CCCc1cccc(CCN)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.55
HRH1 P35367 1/20 0.47
NOS1 P29475 2/20 0.43
NOS2 P35228 2/20 0.43
GRIN2D O15399 2/20 0.39
GRIN3B O60391 2/20 0.39
GRIN1 Q05586 2/20 0.39
GRIN2A Q12879 2/20 0.39
GRIN2B Q13224 2/20 0.39
GRIN2C Q14957 2/20 0.39
GRIN3A Q8TCU5 2/20 0.39
NPSR1 Q6W5P4 1/20 0.38
NOS3 P29474 1/20 0.38
TAAR1 Q96RJ0 3/20 0.37
HRH4 Q9H3N8 1/20 0.36
HTR2A P28223 1/20 0.36
IRAK4 Q9NWZ3 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2522650 0.89 KCNH2 (0.67) KCNH2NOS1NOS2GRIN2DGRIN3B
SCHEMBL522064 0.89 HRH1 (0.56) KCNH2HRH1NOS1NOS2GRIN2D
SCHEMBL929721 0.87 KCNH2 (0.55) KCNH2NOS1NOS2GRIN2DGRIN3B
SCHEMBL24618405 0.87 KCNH2 (0.50) KCNH2HRH1NOS1NOS2GRIN2D
SCHEMBL29792041 0.87 KCNH2 (0.50) KCNH2HRH1NOS1NOS2GRIN2D
SCHEMBL7685870 0.82 KCNH2 (0.59) KCNH2NOS1NOS2GRIN2DGRIN3B
SCHEMBL14234024 0.80 KCNH2 (0.76) KCNH2NOS1NOS2NPSR1
SCHEMBL12844630 0.78 KCNH2 (0.55) KCNH2NOS1NOS2GRIN2DGRIN3B
SCHEMBL24618394 0.78 KCNH2 (0.55) KCNH2NOS1NOS2GRIN2DGRIN3B
SCHEMBL20109293 0.78 KCNH2 (0.55) KCNH2NOS1NOS2GRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230287365-A1 COMPOSITIONS AND METHODS FOR DECREASING INFLAMMATION BETH ISRAEL DEACONESS MEDICAL CENTER, INC. 2023-09-14 US disclosed
US-20230167119-A1 DIAMINOPYRAZOLO[1,5-A]PYRIMIDINE-6-CARBONITRILE COMPOUNDS AS ADENOSINE 2A RECEPTOR AND ADENOSINE 2B RECEPTOR ANTAGONIST Bugworks Research, Inc. 2023-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230287365-A1 COMPOSITIONS AND METHODS FOR DECREASING INFLAMMATION ENTPD1, ENTPD2, ENTPD5 KCNH2 4739/4885HRH1 3287/4885NOS1 974/4885
US-20230167119-A1 DIAMINOPYRAZOLO[1,5-A]PYRIMIDINE-6-CARBONITRILE COMPOUNDS AS ADENOSINE 2A RECEPTOR AND ADENOSINE 2B RECEPTOR ANTAGONIST ADORA2A, ADORA2B, ADORA1 KCNH2 2426/4885HRH1 567/4885NOS1 3584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.